Showing 2,181 - 2,200 results of 16,418 for search '"Therapy"', query time: 0.10s Refine Results
  1. 2181
  2. 2182

    Progression of Left Ventricular Dysfunction and Remodelling under Optimal Medical Therapy in CHF Patients: Role of Individual Genetic Background by Marzia Rigolli, Mariantonietta Cicoira, Corinna Bergamini, Andrea Chiampan, Andrea Rossi, Corrado Vassanelli

    Published 2011-01-01
    “…Due to interindividual heterogeneity in the benefits of therapy, it may be hypothesized that polymorphisms of neurohormonal systems may affect left ventricular (LV) remodelling and systolic function. …”
    Get full text
    Article
  3. 2183
  4. 2184

    Lipid‐coated bismuth nanoflower as the thermos‐radio sensiti for therapy of lung metastatic breast cancer: Preparation, optimisation, and characterisation by Shushu Xue, Junrong Jiao, Si Miao, Lijun Wang, Yang Liu, Qingjie Zhang, Qiyue Wang, Yu Xi, Yuanyuan Zhang

    Published 2022-12-01
    “…Abstract Lung metastatic breast cancer (LMBC) leads to a large number of deaths in women with breast cancer, and radiotherapy has been considered the common assay for tumour therapy except for surgery. However, radiotherapy still faces problems of low efficiency due to resistance and easily induced side effects. …”
    Get full text
    Article
  5. 2185

    Examining alternative approaches to antibiotic utilisation: A critical evaluation of phage therapy and antimicrobial peptides combination as potential alternatives by Chibuzo Vincent Alisigwe, Chibuzor Stanley Ikpa, Uchenna Joseph Otuonye

    Published 2025-03-01
    “…However, concerns about phage evolution potentially eliciting human immune responses necessitate additional investigation to enhance phage therapy. The issue of safety also extends to the recommended purification of AMPs when used in conjunction with bacteriophages to prevent adverse immune reactions in patients. …”
    Get full text
    Article
  6. 2186

    Early detection of myocarditis caused by immune checkpoint inhibitor therapy with nivolumab and ipilimumab for advanced recurrent renal cell carcinoma by Maki Todo, Yodo Gatate, Shintaro Nakano, Go Kaneko, Masayuki Hagiwara, Takayuki Takahashi, Yuta Umezawa, Genji Ueda, Shiho Ishikawa, Yoshinori Makino, Masafumi Oyama, Suguru Shirotake

    Published 2025-02-01
    “…Abstract Combination therapy with nivolumab and ipilimumab for advanced renal cell carcinoma (RCC) may cause immune-related myocarditis; however, its incidence in this cancer type and regimen remains unknown. …”
    Get full text
    Article
  7. 2187
  8. 2188

    Clinical Efficacy and Safety of Stem Cell-Based Therapy in Treating Asherman Syndrome: A System Review and Meta-Analysis by Yiming Zhao, Qifan Luo, Xiao Zhang, Yafei Qin, Jingpeng Hao, Dejun Kong, Hongda Wang, Guangming Li, Xiangying Gu, Hao Wang

    Published 2020-01-01
    “…Current treatment was still limited, and stem cell-based therapy has been proposed as a novel strategy for management of AS. …”
    Get full text
    Article
  9. 2189

    18F-Fluorothymidine-Pet Imaging of Glioblastoma Multiforme: Effects of Radiation Therapy on Radiotracer Uptake and Molecular Biomarker Patterns by Sanjay Chandrasekaran, Andrew Hollander, Xiangsheng Xu, Joseph L. Benci, James J. Davis, Jay F. Dorsey, Gary Kao

    Published 2013-01-01
    “…These studies were undertaken to investigate the effectiveness of 18F-FLT-PET in a GBM mouse model, especially after radiation therapy (RT), and its correlation with useful biomarkers, including proliferation and DNA damage. …”
    Get full text
    Article
  10. 2190
  11. 2191
  12. 2192

    Biologic Therapies for Chronic Obstructive Pulmonary Disease: A Systematic Review and Network Meta-Analysis of Randomized Controlled Trials by Tyler Pitre, Daniel Lupas, Jasmine Mah, Matthew Stanbrook, Alina Blazer, Dena Zeraatkar, Terence Ho

    Published 2025-01-01
    “…However, in the subgroup of patients with blood eosinophils ≥300/mcL, both tezepelumab (MD 0.15 [95% CI 0.05 to 0.26]) and dupilumab (MD 0.13 [95% CI 0.06 to 0.19]) probably improved FEV1 above the MCID.Conclusion Dupilumab is effective at improving patient-relevant outcomes in COPD with higher eosinophil levels. Other biological therapies, including tezepelumab, have no important effect on patient-relevant outcomes.…”
    Get full text
    Article
  13. 2193

    Cost-effectiveness of oral versus injectable disease modifying therapies in relapsing multiple sclerosis: a systematic review analysis by Mehdi Rezaee, Ramin Ravangard, Seyyed Morteza Mojtabaeian, Abdosaleh Jafari

    Published 2024-10-01
    “…Results Thirty studies that had conducted the economic analysis of oral versus injectable therapies in MS patients were included in this review. …”
    Get full text
    Article
  14. 2194

    Cellular Reprogramming, Genome Editing, and Alternative CRISPR Cas9 Technologies for Precise Gene Therapy of Duchenne Muscular Dystrophy by Peter Gee, Huaigeng Xu, Akitsu Hotta

    Published 2017-01-01
    “…In this review, we highlight recent advances made using the CRISPR Cas9 system to correct genetic mutations and discuss how emerging CRISPR technologies and iPSCs in a combined platform can play a role in bringing a therapy for DMD closer to the clinic.…”
    Get full text
    Article
  15. 2195
  16. 2196

    Abdominal obesity as a predictor for response to anti-vascular endothelial growth factor therapy in patients with diabetic macular edema by Tamer E. Wasfy, Shaimaa S. Soliman, Nehad Hawash, Elham A. Gad

    Published 2025-01-01
    “…Anti-vascular endothelial growth factor (anti-VEGF) therapy has been widely used to treat DME. Obesity is associated with higher levels of circulating VEGF, which may worsen diabetic retinopathy and hinder the response to anti-VEGF therapy. …”
    Get full text
    Article
  17. 2197
  18. 2198
  19. 2199
  20. 2200

    Role of Traditional Cardiovascular Risk Factors after Initiation of Statin Therapy: A PharmLines Inception Cohort Study by Dennis Steenhuis, Stijn de Vos, Jens Bos, Eelko Hak

    Published 2022-01-01
    “…Nowadays, millions receive such therapy for the primary prevention of cardiovascular events (CVE). …”
    Get full text
    Article